Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.

Burkhardt UE, Sloots A, Jakobi V, Wei WZ, Cavallo F, Kloke BP, Wels WS.

Cancer Immunol Immunother. 2012 Sep;61(9):1473-84. doi: 10.1007/s00262-012-1215-7. Epub 2012 Feb 14.

PMID:
22331080
2.

Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.

Rohrbach F, Weth R, Kursar M, Sloots A, Mittrücker HW, Wels WS.

J Immunol. 2005 May 1;174(9):5481-9.

3.

DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.

Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jäger E, Forni G, Cavallo F, Wels WS.

Clin Cancer Res. 2008 Nov 1;14(21):6933-43. doi: 10.1158/1078-0432.CCR-08-1257.

4.

Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.

Clin Cancer Res. 2009 Jul 15;15(14):4612-21. doi: 10.1158/1078-0432.CCR-08-3321. Epub 2009 Jul 7.

5.

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.

Cancer Res. 2001 Nov 1;61(21):7925-33.

6.
7.

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.

Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels WS.

Br J Cancer. 2005 Apr 25;92(8):1421-9.

8.
9.

Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.

Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A.

Cancer Gene Ther. 2010 Jul;17(7):465-75. doi: 10.1038/cgt.2010.2. Epub 2010 Feb 19.

PMID:
20168352
10.

Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.

Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N.

J Immunother. 2001 May-Jun;24(3):205-11.

PMID:
11394497
11.

Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.

Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, Koinuma D, Kikuchi T, Tazawa R, Maemondo M, Hagiwara K, Saijo Y, Nukiwa T.

Clin Cancer Res. 2005 Jan 1;11(1):58-66.

12.

The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep.

Drew DR, Boyle JS, Lew AM, Lightowlers MW, Chaplin PJ, Strugnell RA.

Vaccine. 2001 Aug 14;19(31):4417-28.

PMID:
11483267
13.

Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.

Suchorska WM, Dams-Kozlowska H, Kazimierczak U, Wysocki PJ, Mackiewicz A.

Expert Opin Biol Ther. 2011 Dec;11(12):1555-67. doi: 10.1517/14712598.2011.627852. Epub 2011 Oct 14. Review.

PMID:
21995459
14.
15.

Development of a cancer vaccine: peptides, proteins, and DNA.

Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, Akiyoshi K, Sunamoto J, Nakamura H.

Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.

PMID:
10950153
16.

Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.

Pakravan N, Hashemi SM, Hassan ZM.

Cell Stress Chaperones. 2011 Jan;16(1):41-8. doi: 10.1007/s12192-010-0219-5. Epub 2010 Aug 22.

17.

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.

Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T.

Cancer Res. 2005 Jul 1;65(13):5953-7.

18.

A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.

Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT.

J Immunol. 2003 Apr 15;170(8):4242-53.

19.

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W.

Blood. 2002 Aug 15;100(4):1265-73.

Supplemental Content

Support Center